Cardiogenetics

Why Men Die Earlier

Chromosomes

A study published in Science found that the loss of the Y chromosome, which occurs naturally in many men as they age, can cause heart scarring and premature death.

Scientists have known for half a century that the Y chromosome can disintegrate over time, but they weren’t sure if the downstream consequences mattered. 

New research from the University of Virginia suggests that the consequences of a degrading Y chromosome definitely matter. When researchers genetically removed the Y chromosome from the white blood cells of mice, they found that:

  • The mice died earlier and with more cardiac fibrosis.
  • Heart function was restored by treating the mice with a drug that blocks heart scarring. 

To tie these findings to human men, the researchers analyzed genetic data from the UK Biobank (223k men) and found that:

  • Men with a mosaic loss of the Y chromosome had a 41% increased risk of dying from any cause during a 7-year follow-up, and a 31% increased risk of dying from cardiovascular disease. 
  • These men were two to three times more likely to die of congestive heart failure or heart disease.
  • As Y chromosome loss increased, so did the risk of dying from CVD. 

A drug that may help counter the Y loss-associated heart scarring is already on the market. FDA-approved pirfenidone is used to treat idiopathic pulmonary fibrosis, a form of lung scarring, and has undergone trials for heart failure. The study’s authors note that men with Y loss may have a “superior response to this class of therapeutic agents,” although this has not been tested directly yet. 

The Takeaway

These findings demonstrate that Y chromosome loss can directly contribute to age-related heart disease through tissue scarring, and suggest that targeting the effects of Y chromosome loss could help men live longer, healthier lives. 

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Electrophysiology August 21, 2025

Conduction-System Pacing Succeeds at Treating AV Block August 21, 2025

Conduction-system pacing could be poised to reshape standard care for atrioventricular (AV) block patients after the randomized CSPACE trial demonstrated its significant benefits over traditional right ventricular septal pacing. Taking a closer look at CSP’s potential, the CSPACE trial enrolled 202 patients with AV block at two Australian hospitals, randomizing them to conduction-system pacing or […]

Cardiology Pharmaceuticals August 18, 2025

Rivaroxaban Monotherapy Could Be Better for CAD + AFib August 18, 2025

New analysis from the AFIRE trial suggests rivaroxaban monotherapy might be emerging as a preferred antithrombotic strategy for patients with AFib and stable coronary artery disease, especially in older age groups. The Post Hoc AFIRE Analysis examined 2,215 Japanese patients with AFib and stable CAD, stratifying them into four age groups (<70, 70-74, 75-79, and […]

Surgeries & Interventions August 14, 2025

TEER Could Save Lives in AFMR Patients August 14, 2025

Shedding light on a new treatment for an understudied condition, data published in EHJ suggests that transcatheter edge-to-edge repair (TEER) delivers significant survival advantages in patients with atrial functional mitral regurgitation (FMR). The new OCEAN-Mitral/REVEAL-AFMR Analysis compared 441 TEER-treated patients against 640 medically managed controls with moderate or severe atrial FMR, stating a solid case […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!